

---

## **Innovative therapy, monoclonal antibody and beyond - 5<sup>th</sup> Edition**

Friday, 30 January 2015

**Fondazione IRCCS Istituto Nazionale dei Tumori- C.so Venezian, 1 Milano**

Bio-immunotherapy of cancer is providing compelling proofs of clinical success in the comprehensive treatment of human malignancies.

The increasing knowledge of the molecular mechanisms responsible for neoplastic transformation, the biology of cancer cells, and the immunological mechanisms regulating tumor-host interaction, allowed us to identify and apply more effective anti-cancer biological and immunological treatments. To date, the immuno-biotherapy is a continuously evolving treatment modality and it is currently integrated into the treatment algorithms of several different tumors. Furthermore, elucidating resistance mechanisms and exploiting cancer vulnerabilities to therapeutics will ultimately improve cancer therapy and patient care.

For these reasons, a multidisciplinary approach, including clinical and pre-clinical professionals, is required. This conference explores topics that will appeal to clinicians, as well as, basic, translational, and clinical scientists ranging from academics to industry. As in the past, the meeting will provide a highly interactive forum in which leading experts will discuss clinical and pre-clinical data, providing the audience with a broad overview of the most recent achievements in cancer biologic and immunologic therapy.

---

**NADIREX INTERNATIONAL Srl**

## Innovative therapy, monoclonal antibody and beyond - 5<sup>th</sup> Edition

Friday, 30 January 2015

### **PROGRAM**

Welcome Coffee

- 08.00-09.00 Registration  
09.00-09.10 Welcome remarks of Authorities  
09.10 Introduction • M. Di Nicola and M. Del Vecchio (Milan)

### **I SESSION: Preclinical assays and novel biotargets**

Chairmans: G. Inghirami (NY, USA), MP Colombo (Milan)

- 09.20-09.50 Heat shock proteins and tumorigenesis • Cerchietti L, (NY, USA)  
09.50-10.00 Discussion  
  
10.00-10.30 Rationale for immunotherapeutic combinations • A Anichini (Milan)  
10.30-10.40 Discussion  
  
10.40-11.10 OX-40 is a fitness adaptor for T cells in the tumor microenvironment • M. Colombo (Milan)  
11.10-11.20 Discussion  
  
11.20-11.50 Humanized mice as preclinical model to guide targeted cancer therapy and drug development • G Inghirami (NY, USA)  
11.50-12.00 Discussion

### **Keynote Lecture**

- 12.00-12.45 Immune check-point inhibitors: clinical experience • J. Weber (Tampa, USA)  
Introduction: F. De Braud (Milan)  
  
12.45-14.00 Buffet Lunch

### **II SESSION: Monoclonal antibodies, cell therapies and TK inhibitors,**

Chairmans: M. Massaia (Turin), M. Di Nicola (Milan)

- 14.00-14.30 Drug-conjugated antibody: Brentuximab and CD30+ hematological tumors • P. Corradini (Milan)  
14.30-14.40 Discussion

**NADIREX INTERNATIONAL Srl**

- 
- 14.40-15.50    Bispecific monoclonal antibody  
                  1. Principles and novel targets - M. Figini (Milan)  
                  2. Blinatumumab: clinical results - M. Topp
- 15.50-16.00    Discussion
- 16.00-16.30    CAR-T cell therapies from hematologic malignancies to solid tumors • G. Dotti (Houston, USA)
- 16.30-16.40    Discussion
- 16.40-17.10    Targeted therapies in melanoma  
                  M. Del Vecchio (Milan)
- 17.10-17.20    Discussion
- 17.20            Conclusions M. Di Nicola (Milan)
- Adjourn